The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas

Purpose There is still debated regarding the optimal treatment strategy for cholangiocarcinoma (CC) after curative resection. The aim of this study was to analyze the role of adjuvant therapy in R0-resected intrahepatic and perihilar CCs. Methods We retrospectively reviewed the patients who underwen...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2017, Vol.79 (1), p.99-106
Main Authors: Kim, Young Saing, Oh, Sung Yong, Go, Se-Il, Kang, Jung-Hun, Park, Inkeun, Song, Haa-Na, Ji, Jun Ho, Hwang, In Gyu, Jang, Joung-Soon
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Bile Duct Neoplasms - mortality
Bile Duct Neoplasms - pathology
Bile Duct Neoplasms - therapy
Bile Ducts, Intrahepatic
Cancer Research
Chemoradiotherapy, Adjuvant
Cholangiocarcinoma - mortality
Cholangiocarcinoma - pathology
Cholangiocarcinoma - therapy
Female
Humans
Lymphatic Metastasis
Male
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original Article
Pharmacology/Toxicology
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose There is still debated regarding the optimal treatment strategy for cholangiocarcinoma (CC) after curative resection. The aim of this study was to analyze the role of adjuvant therapy in R0-resected intrahepatic and perihilar CCs. Methods We retrospectively reviewed the patients who underwent R0 resection for intrahepatic and perihilar CCs between January 2001 and December 2013 at six tertiary medical centers; adjuvant therapy consisted of chemotherapy (CT), chemoradiotherapy (CRT), or radiotherapy (RT). The outcomes of our study were recurrence-free survival (RFS) and overall survival (OS). Results We included a total of 137 consecutive patients in the analysis; 58.4% of them had intrahepatic CCs, and 25.5% had lymph node (LN) involvement. Seventy-three patients (53.3%) had received adjuvant therapy (CT, CRT, RT: 48, 13, 12, respectively), and most patients who had received adjuvant therapy had stage III or IVA, T3 or 4 tumors, and positive LNs. Multivariable analysis identified positive LN [hazard ratio (HR) 3.47; P  
ISSN:0344-5704
1432-0843
DOI:10.1007/s00280-016-3206-4